US20160015637A1 - Anti-itching powder - Google Patents
Anti-itching powder Download PDFInfo
- Publication number
- US20160015637A1 US20160015637A1 US14/799,591 US201514799591A US2016015637A1 US 20160015637 A1 US20160015637 A1 US 20160015637A1 US 201514799591 A US201514799591 A US 201514799591A US 2016015637 A1 US2016015637 A1 US 2016015637A1
- Authority
- US
- United States
- Prior art keywords
- powder
- fine powder
- emulsion
- itching
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000843 powder Substances 0.000 title claims abstract description 120
- 208000003251 Pruritus Diseases 0.000 title claims abstract description 113
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims abstract description 48
- 239000000839 emulsion Substances 0.000 claims abstract description 45
- 210000003491 skin Anatomy 0.000 claims abstract description 37
- 210000000434 stratum corneum Anatomy 0.000 claims abstract description 32
- 239000002585 base Substances 0.000 claims abstract description 28
- 210000004243 sweat Anatomy 0.000 claims abstract description 28
- 210000002374 sebum Anatomy 0.000 claims abstract description 26
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 19
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 210000001339 epidermal cell Anatomy 0.000 claims abstract description 16
- 239000002075 main ingredient Substances 0.000 claims abstract description 12
- 229940037003 alum Drugs 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 230000002085 persistent effect Effects 0.000 claims description 7
- 230000035515 penetration Effects 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 3
- 238000013329 compounding Methods 0.000 claims 2
- 239000000395 magnesium oxide Substances 0.000 claims 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 235000012239 silicon dioxide Nutrition 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 210000004027 cell Anatomy 0.000 abstract description 8
- 230000000903 blocking effect Effects 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 230000005068 transpiration Effects 0.000 abstract description 3
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 230000009545 invasion Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 44
- 201000004624 Dermatitis Diseases 0.000 description 31
- 229940063656 aluminum chloride Drugs 0.000 description 22
- 238000012360 testing method Methods 0.000 description 19
- 239000011148 porous material Substances 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 14
- 238000009825 accumulation Methods 0.000 description 12
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 12
- 230000002265 prevention Effects 0.000 description 12
- 239000000454 talc Substances 0.000 description 12
- 229910052623 talc Inorganic materials 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 229920002261 Corn starch Polymers 0.000 description 10
- 239000008120 corn starch Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 235000014692 zinc oxide Nutrition 0.000 description 10
- 239000011787 zinc oxide Substances 0.000 description 10
- JGDITNMASUZKPW-UHFFFAOYSA-K aluminium trichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Al](Cl)Cl JGDITNMASUZKPW-UHFFFAOYSA-K 0.000 description 9
- 229940009861 aluminum chloride hexahydrate Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 208000010668 atopic eczema Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000035900 sweating Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 6
- 239000000919 ceramic Substances 0.000 description 6
- 206010016936 Folliculitis Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000009194 climbing Effects 0.000 description 5
- 230000003412 degenerative effect Effects 0.000 description 5
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000005871 repellent Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010066295 Keratosis pilaris Diseases 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000001166 anti-perspirative effect Effects 0.000 description 4
- 239000003213 antiperspirant Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- LVYZJEPLMYTTGH-UHFFFAOYSA-H dialuminum chloride pentahydroxide dihydrate Chemical compound [Cl-].[Al+3].[OH-].[OH-].[Al+3].[OH-].[OH-].[OH-].O.O LVYZJEPLMYTTGH-UHFFFAOYSA-H 0.000 description 3
- 231100000676 disease causative agent Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006003 cornification Effects 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002940 repellent Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- CAYKLJBSARHIDI-UHFFFAOYSA-K trichloroalumane;hydrate Chemical compound O.Cl[Al](Cl)Cl CAYKLJBSARHIDI-UHFFFAOYSA-K 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 101710154918 Trigger factor Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- -1 aluminum compound Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000000040 apocrine gland Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000000412 mechanoreceptor Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- RNWHGQJWIACOKP-UHFFFAOYSA-N zinc;oxygen(2-) Chemical class [O-2].[Zn+2] RNWHGQJWIACOKP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Definitions
- the present invention relates to anti-itching powder to outstandingly prevent skin diseases such as eczema and dermatitis.
- baby powder has been widely used as commercial products.
- the main ingredients of the baby powder are starch such as corn starch, zinc oxide, talc, aluminum chlorohydrate, and a similar ingredient.
- the principle of the baby powder is as follows. Processed starch and silicic anhydride powder absorb the sweat. The zinc oxide and the talc sterilize the skin and improve the slipperiness. The antiperspirant effect by the aluminum chlorohydrate powder inhibits the sweating.
- the present invention provides anti-itching powder.
- the anti-itching powder prevents the emulsion, which is produced by mixing sweat, which is continuously secreted during rest (referred to as persistent sweat) and the sebum and becomes a cell disorder composition, from transmitting the stratum corneum and invading the epidermal cells as a result of further concentration on the skin stratum corneum.
- the present invention provides the anti-itching powder that outstandingly prevents the skin diseases, such as the eczema and the dermatitis, without blocking emission and transpiration of the moisture in the sweat from the skin stratum corneum.
- the anti-itching powder is fine powder whose main ingredients are an astringent, such as an aluminum chloride compound and alum, and cyclodextrin.
- the following describes a basic structure and a prescription example of anti-itching powder of the present invention.
- powder of 100 g which becomes a base
- approximately 2 to 15% of aluminum chloride hexahydrate, anhydrous aluminum chloride, or the mixture of them, which will be the main ingredient, is incorporated with and combined with cyclodextrin (hereinafter referred to as CD), which is similarly the main ingredient, for production.
- CD is an inclusion compound that can include a hydrophobic material, such as the sebum and the emulsion, by meeting a certain condition.
- the CD mainly means ⁇ -CD, ⁇ -CD, ⁇ -CD, and the mixture composition of these materials.
- inclusion compounds other than the CD which is the derivative of ⁇ -CD, ⁇ -CD, and ⁇ -CD, can also be used.
- the precondition as long as the inclusion compound absorbs the emulsion containing the sebum and dissolves the emulsion into water, all inclusion compounds can be used. Since the absorption condition changes depending on a solute to be added, it is preferable to select and use the inclusion compound so as to establish an optimal condition.
- both the anhydrous aluminum chloride and the aluminum chloride hexahydrate can be used.
- a polymer such as burnt alum and basic aluminum chloride can also be used.
- combining the polymer around 10 to 20% with respect to a powder basic base of 100 g is preferable.
- the polymer is disadvantageous in short durability of functionality, around one-third of the aluminum chloride.
- the hydrate of the alum can be similarly used. It is preferable that the raw material of the powder basic base has a composition similar to the baby powder.
- zinc oxide powder which has an effect to protect roots of hair from an influence of solar light, especially ultraviolet rays, or a similar material, and besides talc powder, starches, a celluloses such as HPC, MC, and CMC, and the mixture of them as a single basic base does not bring any problem in effect and a big harmful effect.
- the usual moisturizer and an antioxidant substance which is also a moisture composition, such as vitamin E and ascorbic acid 2-phosphate, are preliminary powdered with powdering assistant, such as the CD and silicic anhydride.
- powdering assistant such as the CD and silicic anhydride.
- the powdered antioxidant substance can also be appropriately selected and combined.
- the anti-itching powder is thinly applied to the skin surface directly with a puff so as to stroke the skin surface.
- the anti-itching powder is applied to the skin surface so as to lightly press the skin surface with the pulps or the palm.
- a method for application by a spray method with high pressure gas or a similar method is also simple.
- the following describes an aggressive factor related to an appearance of sudden itch not due to dermatitis and a mechanism of production of an aggressive material in detail.
- the one factor is persistent sweat mainly secreted from apocrine sweat glands and eccrine sweat glands.
- the composition is mainly the moisture, the persistent sweat contains salt, even a trace of which becomes a stimulatory composition to the skin, uric acid, lactic acid, butyric acid, isovaleric acid, unsaturated aldehyde, and amines, which are produced by zymolysis of adhered bacteria and indigenous dermal bacteria.
- sebum which is unsaturated fatty acids secreted from sebaceous glands, and steroids. It is considered that when these aggressive factors are concentrated on stratum corneum and become a concentrated emulsion, the aggressive factors turn into the aggressive materials.
- the mechanism of action is caused when the aggressive material meets the condition: (A) or (B) or (A)+(B).
- the emulsion is an epidermal cell disorder composition produced with the sweat and the sebum.
- the emulsion which is produced with the persistent sweat and the sebum, is further concentrated on the stratum corneum. Consequently, the emulsion transmits the stratum corneum and soaks up to the epidermal cells, thus inducing the itching.
- Fine powder containing aluminum chloride and cyclodextrin as the main ingredients and talc, starch, cellulose, zinc oxide, titanium oxide, or a similar material as the basic bases is combined with fine powder, which will be the main ingredient.
- the anti-itching powder thus formed is applied over the skin face. This instantly hardens the stratum corneum epidermidis.
- This porous, degenerative stratum corneum causes a complex barrier to accumulate this emulsion.
- the complex barrier is constructed with the aluminum chloride, the cyclodextrin, and the moisture from sweat. Accordingly, the emulsion cannot penetrate up to the epidermal cells, the itching is not initiated.
- the application of the aluminum chloride fine powder and the cyclodextrin fine powder does not bring the action and the effect of inhibiting the sudden itch and the inflammation by themselves.
- the constitution of the emulsion barrier complex by the interaction of the degenerative stratum corneum, the aluminum chloride, the cyclodextrin, and the moisture expresses the mechanism of action to effectively block the cycle of the itch and the dermatitis. Accordingly, the mechanism of action can also lead to a prevention of various kinds of inflammatory skin diseases.
- the invention of present application has assumed as follows.
- the itch that cannot be solved by the antiperspirant effect from the aluminum chloride is caused by the emulsion concentrated on the skin stratum corneum.
- the invention has focused on the interaction compounded by a water-repellent film effect from the aluminum chloride compound, the inclusion and absorption effects from the cyclodextrin, and the moisture.
- the invention has solved the mechanism for itch.
- numerous sweating tests have been conducted. For example, the water solution of the aluminum compound is applied over the whole body, and a heat accumulation test has been conducted. From the result of the heat accumulation test, the following features have been proved.
- the main effect is not the antiperspirant effect but the water repellent effect.
- the porous thin film which easily transmits the sebum and the moisture, is formed.
- the invention has an effect of forming not only the degenerative stratum corneum but also a water-repellent film to a different solute in the water solution.
- the water-repellent film establishes a mechanism as if an interfacial phenomenon where the moisture is peeled from the solute occurs and this blocks the moisture. The following is considered.
- This mechanism acts as an effect to block the production of the emulsion, which will be the causative agent of itch.
- the mechanism demulsifies the emulsion and isolates the moisture and the sebum.
- the mechanism promotes the inclusion and absorption effects of the sebum with the cyclodextrin.
- the cyclodextrin that has absorbed and included the sebum forms free water and a colloidal emulsion.
- the concentration of moisture on the degenerative stratum corneum promotes a condensation effect and the cyclodextrin is gelatinized. This brings a favorable condition to absorb and secure the aqueous (Some of them are possibly oily.) causative agent of itch to between particles and the periphery of the CD. According to this, it is concluded that the itch is prevented.
- the present invention has been completed.
- the itch prevention effect cannot be obtained in examples of single use of the respective aluminum chloride and cyclodextrin, which are described in detail in itch prevention effect experiment, which will be described later.
- ⁇ Working Example 1> conducted heat accumulation experiment with the anti-itching powder. With the anti-itching powder applied over the whole body, two tested persons, male and female, climbed a mountain and run to test for how much the heat accumulation occurs. The result is as follows.
- the tested person male: The body temperature after the exercise was 34.5 to 35.0° C., and the temperature before the climbing was 35.1 to 35.8° C.
- the tested person female: The body temperature after the exercise was 34 to 34.5° C., and the temperature before the climbing was 34.5 to 34.7° C.
- the tested person male: The body temperature after the exercise was 34 to 35.0° C., and the body temperature before the running was 35 to 36° C.
- the tested person female: The body temperature after the exercise was 34 to 34.5° C., and the body temperature before the running was 35 to 36.2° C.
- Experiment 1 The somesthetic testing was conducted to determine whether the single use of the aluminum chloride fine powder was able to prevent the itch or not based on the following prescription example. The result is shown in the following. First, since the moisture absorption and the deliquescency are large, pulverization of the aluminum chloride hexahydrate is difficult. Moreover, for direct application to the skin, the aluminum chloride hexahydrate has a high pH and therefore initializes a skin disorder. Accordingly, as the fine powder base, which will be the basic, fine powder formed by combining the aluminum chloride hydrate was used to determine the itch prevention effect by the somesthetic testing. The following fine powder base, which becomes the basic, was employed.
- 160-mesh pass activated zinc oxide of 40 g, talc of 40 g, and 100-mesh pass corn starch of 20 g were used. Powdery aluminum chloride hydrate of 15 g was combined with these materials. The combined material was crushed and mixed for 25 minutes with ball mill. The material was shaken with a 48-mesh screen to produce mixed fine powder.
- the anti-itching powder of the present invention has an advantage that can be used also during treatment with an ointment or a similar medicine. In some cases, this reduces a usage frequency of curative medicine and duration of treatment. It is also possible to present an optimal, satisfactory periods of use or to propose a new usage method also for diseased patients who dislike steroids for external application. The following further describes problematic diseases with concrete examples in detail.
- the application of the anti-itching powder composited with the main ingredients of the aluminum chloride and the cyclodextrin over the whole body reduces the stickiness on the skin surface and reduces a shine.
- the anti-itching powder is applied over the entire facial surface. Even after the elapse of several hours, the entire forehead is smooth and the rash skin touch disappears.
- the anti-itching powder of the present invention inhibits: 1) the expression of sudden itching and 2) penetration of the emulsion, which is constituted of the sweat and the sebum, related to an appearance of acute-phase folliculitis into the living epidermal cell layer and cells on a wall of hair follicle (a wall of the pores).
- the initial lesion is papular dermatitis
- the target is mainly the roots of hair.
- the sudden itch is preceded.
- the dermatitis develops into papules.
- the healthy skin around the papules which is not directly related to the papules, is also scratched, resulting in expansion of the disease.
- the strength of scratch whether the skin is strongly scratched by tiptoes, the skin is scratched so as to rub the skin by the pulps, the skin is scratched with a towel, or the skin is scratched over clothes; how long is the skin scratched and how long is the period of scratch; and under these situations, how long period and how strong extent the dermatitis keep occurring.
- These situations design and initialize various and variety of inflammatory skin diseases.
- the aluminum chloride hexahydrate of 7 g and ⁇ -CD of 10 g were introduced into a ceramic ball mill together with the powder basic base of 100 g and were crushed around 15 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained.
- the zinc white of 40 g, the talc of 40 g, and the corn starch of 20 g were combined to produce the powder basic base.
- the aluminum chloride hexahydrate of 5 g and ⁇ -CD of 5 g were introduced into the ceramic ball mill together with the powder basic base of 100 g and were crushed and mixed for 15 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained.
- the zinc white of 50 g, the talc of 20 g, and the corn starch of 30 g were combined to produce the powder basic base.
- the talc of 60 g, the corn starch of 30 g, silicic anhydride of 5 g, and sodium oxide of 5 g were combined to produce the powder basic base.
- Anhydrous alum of 20 g and ⁇ -CD of 5 g were introduced into the mixer together with the powder basic base of 100 g to obtain 65-mesh pass anti-itching powder.
- the zinc white of 40 g, the talc of 30 g, and the corn starch of 30 g were combined to produce the powder basic base.
- the aluminum chlorohydrate of 10 g and ⁇ -CD of 10 g were introduced to the ceramic ball mill together with the powder basic base of 100 g and were crushed around 25 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained.
- the zinc white of 40 g, the talc of 40 g, and the corn starch of 20 g were combined to produce the powder basic base.
- the aluminum chloride hexahydrate of 7 g and ⁇ -CD of 10 g were introduced to the ceramic ball mill together with the powder basic base of 100 g and were crushed around 15 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained.
- the zinc white of 40 g, the talc of 40 g, and the corn starch of 20 g were combined to produce the powder basic base.
- the aluminum chloride hexahydrate of 7 g and ⁇ -CD of 8 g were introduced to the ceramic ball mill together with the powder basic base of 100 g and were crushed around 15 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained.
- the zinc white of 40 g, the talc of 40 g, and the corn starch of 20 g were combined to produce the powder basic base.
- the anhydrous alum of 20 g and ⁇ -CD of 10 g were introduced to the ceramic ball mill together with the powder basic base of 100 g and were crushed around 15 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained.
- the zinc white of 40 g, the talc of 40 g, and the corn starch of 20 g were combined to produce the powder basic base.
- the emulsion is the cell disorder composition, which becomes an ignition factor of acute inflammation or triggers the acute inflammation, or the emulsion causes a growth of bacteria and smell Inhibiting the production of the emulsion for a certain period of time (around 36 hours to two weeks) provides the following effects.
- the emulsion As the factors for the pores to cause the inflammation, which is a part of a transition process to the dermatitis of the pores, influences from the ultraviolet rays, the steroid, and reactive oxygen have been known. However, the generation of the reactive oxygen means that the cell disorder has already been initialized from any cause.
- the anti-itching powder inhibits a sequence of cycles of inflammation where the inflammation that has once occurred in the pores persists and then is reinforced little by little. It is said that a chain of inflammation is a process of: increasing the inflammation in the pores and growing the red eminences on the pores, which is bacterial infection caused by touching and rubbing the pores. However, it is reasonable to think that the persistent penetration of the emulsion is largely related to the persistence and the aggravation of inflammation prior to secondary infection with bacteria. The process that the inflammation reaction persists and is reinforced is named as the ‘cycle of inflammation.’ The main factor bringing the cycle of inflammation is the emulsion.
- the anti-itching powder has an effect of naturally regresses the red eminences, namely, the folliculitis, becoming larger on the pores.
- the anti-itching powder prevents the emulsion from keeping repeatedly stimulating the folliculitis.
- the anti-itching powder has an action and an effect that naturally flattens the red inflammatory eminences on the pores without developing the eminences into suppuration and an accumulation of pus.
- the anti-itching powder has an effect of soothing the sudden, strong itch.
- the anti-itching powder has an effect of preliminary preventing the itch caused by penetration of the emulsion into the epidermis from accumulation to the stratum corneum.
- the anti-itching powder also has an effect of preliminary preventing the expression of sudden itch when the sweat oozes. This reduces an occasion where patients with atopy and children sweat and scratch their heads, ears, external genitalias, and limb joints. This allows bringing effects not only preliminary preventing the appearance of eczema and dermatitis but also decreasing the range.
- the causes include, for example, the ultraviolet rays, medicines (a fomentation, an external medicine, and an oral medicine), chemical substances, insects, and plants.
- the anti-itching powder has an effect of reducing keratosis pilaris (rashes on the cheek and the arm). Although the anti-itching powder does not cure this disease itself, an acute phase before the pores are cornified is the folliculitis (acute dermatitis of the pores).
- a trigger factor that initializes the inflammation of the folliculitis is an accumulation of the emulsions consisted of the sweat and the sebum on the stratum corneum epidermidis around the pores.
- the aluminum chloride adheres to the entire stratum corneum to prevent the accumulation of the moisture inside the stratum corneum. So to speak, this forms the sponge-like stratum corneum epidermidis into like a single plate.
- the cornification of the keratosis pilaris means that the epidermal cells at the exit of the pores go through a denaturation and change into the inflammation, lose the nuclei, and are stacked, so-called accumulation of epidermis refuses.
- this prevents the cornification of the pores, and consequently ensuring preventing the keratosis pilaris.
- the effect can be felt in a short period (one to two weeks). This is because that the inflammation of the skin leading to the keratosis pilaris is much lighter than the inflammation of the acne.
- the anti-itching powder has an action and effect of outstandingly preventing oxidized colors of the unsaturated fatty acid secreted from the sebaceous gland, mainly yellow stains on clothing generated by the secretion of the apocrine gland.
- the stickiness of the sweat generated by excessive sweating on the hand is not only the moisture but also is the emulsion consisted of the sweat and the sebum.
- the surface-active effect by the aluminum chloride and the CD blocks and inhibits the emulsion accumulated on the stratum corneum epidermidis. This provides a smooth texture to a person who has touched the hand.
- the anti-itching powder with the main ingredients of the aluminum chloride and the cyclodextrin is in a category of quasi-drug. Therefore, like an insect repellent, the anti-itching powder can be casually used, anytime and anywhere regardless of frequency. Accordingly, the anti-itching powder is also excellent in convenience.
- the skin-degenerative stratum corneum, the aluminum chloride, water, and the cyclodextrin construct the emulsion barrier complex. This expresses the mechanism of action to effectively block the cycle of dermatitis. This allows bringing prevention of various inflammatory skin diseases.
- the anti-itching powder of the present invention has an advantage that can be used also during treatment with the ointment or a similar medicine. In some cases, this substantially reduces a usage frequency of curative medicine and duration of treatment. It is also possible to present an optimal, satisfactory periods of use or to propose a new usage method also for diseased patients who dislike steroids for external application.
- the anti-itching powder features extremely high effectiveness as one means for alternative medicine.
- the anti-itching powder is an invention that provides great anticipation and prospect for treatment strategy of these diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is anti-itching powder that blocks transmission to stratum corneum and invasion up to epidermal cells by emulsion as a result of further concentration on skin stratum corneum. The emulsion is produced by mixing sweat continuously secreted during rest and sebum. The emulsion becomes a cell disorder composition. Specifically, the anti-itching powder as a fine powder contains main ingredients of aluminum chloride or alum and cyclodextrin. A fine powder as a base is dispersed into and combined with the fine powder. The application of the fine powder over the skin prevents sudden itch without blocking emission and transpiration of moisture in the sweat from the skin stratum corneum.
Description
- This patent specification is based on Japanese patent application, No. 2014-160819 filed on Jul. 20, 2014 in the Japan Patent Office, the entire contents of which are incorporated by reference herein.
- 1. Field of the Invention
- The present invention relates to anti-itching powder to outstandingly prevent skin diseases such as eczema and dermatitis.
- 2. Description of Related Art
- Through skin practices for 19 years, a voice of patients from which I have realized is, regardless of age, a voice questioning “Although eruption gets better with medicine, is there anything that can be done about an itch?” A dogma by dermatologists/plastic surgery doctors is that treatment of curing the eruption and soothing the itch is rules and principles derived from medical treatment for health. The medical treatment is to cure diseases. With the stereotype, the medical treatment has been developed in the form of a progress of new medicines. However, in association with a recent expansion of medical cost, approaches to prevent diseases before getting sick have been gradually taken into consideration.
- Most eczema and dermatitis in the field of dermatology increase during summertime, a warm period, and a period of having a warm in a winter season. Accordingly, ways of thinking: <getting itchy due to sweating> and <Sweating aggravates the eczema and the dermatitis.> are present. However, the main cause for such sudden itch has not been solved and also has not been problematized. As a result of affection with a disease where the cause of the itch is persistently the eczema and the dermatitis, it is regarded that the main reason for causing the itch is an isolation of chemical mediators, such as histamines, from leukocytes and irritating materials such as cytokines.
- Meanwhile, the way of thinking that the sweating brings the itch has been a common opinion conventionally. It has been considered that in the concept of hidroschesis, inhibiting secretion of sweat and smoothing the skin inhibit miliaria, ensuring reducing the itch. Accordingly, baby powder has been widely used as commercial products. The main ingredients of the baby powder are starch such as corn starch, zinc oxide, talc, aluminum chlorohydrate, and a similar ingredient. The principle of the baby powder is as follows. Processed starch and silicic anhydride powder absorb the sweat. The zinc oxide and the talc sterilize the skin and improve the slipperiness. The antiperspirant effect by the aluminum chlorohydrate powder inhibits the sweating. When using the baby powder after toileting the sweat on the whole body, the touch is smooth and the person feels like that the itch has subsided to some extent. However, since the itch comes back soon, the baby powder has no effect to stop a scratch action. Dermatologists recommend the baby powder as an anti-itching agent and encourage many patients who have the itch to use the baby powder. However, since the use of the baby powder does not remove the itch under the actual situation, the majority opinion is that scratches are not cleared up.
- The dermatological theory up to the present sees that an emulsion composed of eccrine sweat, apocrine sweat, and sebum, which is secreted from the sebaceous gland, as a concept of moisturizing and protection effects. However, supposedly, even if moisture and the sebum have gone from the skin stratum corneum, as long as the epidermal cells themselves are not damaged, the skin is merely dried to the extent where the sulcus cutis looks white macroscopically. Functions such as stretchability of the epidermal cell layer are not lost at all. This is because that the stratum corneum serves as a barrier for the living epidermal cells.
- Additionally, the generally spoken term, <dry skin> is extremely ambiguous. By appearance of eczema (dermatitis) of almost 100%, the originally living epidermal cells themselves are disordered, and extinct epidermal cells (scales), which lose their nuclei, are deposited. This state is merely referred to as the dry skin or xeroderma. As a result of extensive researches based on such knowledge, the inventor has found that this emulsion itself is a causative agent mainly causing the sudden itch. Thus, the inventor has reached the present invention.
- The present invention provides anti-itching powder. The anti-itching powder prevents the emulsion, which is produced by mixing sweat, which is continuously secreted during rest (referred to as persistent sweat) and the sebum and becomes a cell disorder composition, from transmitting the stratum corneum and invading the epidermal cells as a result of further concentration on the skin stratum corneum. Specifically, the present invention provides the anti-itching powder that outstandingly prevents the skin diseases, such as the eczema and the dermatitis, without blocking emission and transpiration of the moisture in the sweat from the skin stratum corneum. The anti-itching powder is fine powder whose main ingredients are an astringent, such as an aluminum chloride compound and alum, and cyclodextrin.
- The following describes a basic structure and a prescription example of anti-itching powder of the present invention. With respect to powder of 100 g, which becomes a base, approximately 2 to 15% of aluminum chloride hexahydrate, anhydrous aluminum chloride, or the mixture of them, which will be the main ingredient, is incorporated with and combined with cyclodextrin (hereinafter referred to as CD), which is similarly the main ingredient, for production. The CD is an inclusion compound that can include a hydrophobic material, such as the sebum and the emulsion, by meeting a certain condition. In the present invention, the CD mainly means α-CD, β-CD, γ-CD, and the mixture composition of these materials. Besides, inclusion compounds other than the CD, which is the derivative of α-CD, β-CD, and γ-CD, can also be used. However, as the precondition, as long as the inclusion compound absorbs the emulsion containing the sebum and dissolves the emulsion into water, all inclusion compounds can be used. Since the absorption condition changes depending on a solute to be added, it is preferable to select and use the inclusion compound so as to establish an optimal condition.
- As the aluminum chloride, both the anhydrous aluminum chloride and the aluminum chloride hexahydrate can be used. Besides, although the effect is inferior, a polymer such as burnt alum and basic aluminum chloride can also be used. As one example, combining the polymer around 10 to 20% with respect to a powder basic base of 100 g is preferable. However, the polymer is disadvantageous in short durability of functionality, around one-third of the aluminum chloride. Besides, the hydrate of the alum can be similarly used. It is preferable that the raw material of the powder basic base has a composition similar to the baby powder. However, the use of zinc oxide powder, which has an effect to protect roots of hair from an influence of solar light, especially ultraviolet rays, or a similar material, and besides talc powder, starches, a celluloses such as HPC, MC, and CMC, and the mixture of them as a single basic base does not bring any problem in effect and a big harmful effect.
- The usual moisturizer and an antioxidant substance, which is also a moisture composition, such as vitamin E and ascorbic acid 2-phosphate, are preliminary powdered with powdering assistant, such as the CD and silicic anhydride. The powdered antioxidant substance can also be appropriately selected and combined.
- The following methods for applying the anti-itching powder are applicable. The anti-itching powder is thinly applied to the skin surface directly with a puff so as to stroke the skin surface. Alternatively, the anti-itching powder is applied to the skin surface so as to lightly press the skin surface with the pulps or the palm. Alternatively, although there is an adverse effect of suction, a method for application by a spray method with high pressure gas or a similar method is also simple.
- The following describes an aggressive factor related to an appearance of sudden itch not due to dermatitis and a mechanism of production of an aggressive material in detail. There are two main factors to cause sudden itching to appear, regardless of presence of an inflammation on a skin. The one factor is persistent sweat mainly secreted from apocrine sweat glands and eccrine sweat glands. Although the composition is mainly the moisture, the persistent sweat contains salt, even a trace of which becomes a stimulatory composition to the skin, uric acid, lactic acid, butyric acid, isovaleric acid, unsaturated aldehyde, and amines, which are produced by zymolysis of adhered bacteria and indigenous dermal bacteria. The other is sebum, which is unsaturated fatty acids secreted from sebaceous glands, and steroids. It is considered that when these aggressive factors are concentrated on stratum corneum and become a concentrated emulsion, the aggressive factors turn into the aggressive materials.
- The mechanism of action is caused when the aggressive material meets the condition: (A) or (B) or (A)+(B).
- (A) The aggressive material soaks into deep parts of epidermal cells and directly stimulates the Meissner's corpuscle, which is an end of a sensory nerve (C-fiber).
- (B) When the aggressive material directly penetrates to the inside of the cells from the epidermal cell membrane, the cells themselves sense the aggressive material as an abnormal signal, and the result is recognized as itching.
- The emulsion is an epidermal cell disorder composition produced with the sweat and the sebum. The emulsion, which is produced with the persistent sweat and the sebum, is further concentrated on the stratum corneum. Consequently, the emulsion transmits the stratum corneum and soaks up to the epidermal cells, thus inducing the itching. Fine powder containing aluminum chloride and cyclodextrin as the main ingredients and talc, starch, cellulose, zinc oxide, titanium oxide, or a similar material as the basic bases is combined with fine powder, which will be the main ingredient. The anti-itching powder thus formed is applied over the skin face. This instantly hardens the stratum corneum epidermidis. This constructs porous, degenerative stratum corneum that does not transmit and block the transpiration of moisture. This porous, degenerative stratum corneum causes a complex barrier to accumulate this emulsion. The complex barrier is constructed with the aluminum chloride, the cyclodextrin, and the moisture from sweat. Accordingly, the emulsion cannot penetrate up to the epidermal cells, the itching is not initiated.
- Once applying the anti-itching powder ensures maintaining the skin surface of the stratum corneum always smooth. On a facial surface where the secretion of the sebum is particularly large, after an elapse of roughly 12 hours, an amount of absorption of the emulsion in the complex is likely to decay. Therefore, although a slightly sticky texture appears, even after an elapse of seven days, the itch does not occur. The reason is considered as follows. The formation of the complex barrier theoretically continues blocking the mechanism of emulsion production on the stratum corneum epidermidis until a turnover cycle of the epidermis. However, the entire skin surface constantly receives some sort of physical friction from, for example, clothes and a towel. Accordingly, around 36 hours is actually regarded as a limit for practical use.
- When the accumulation of the emulsion by the complex barrier decays and is saturated, and an equilibrium state is reached, extra emulsion and newly produced sebum are oozed out to the stratum corneum surface. This phenomenon is caused by a surface-active effect generated on the interface of the stratum corneum. The phenomenon is considered to be caused by CD molecules filmy aligning with their hydrophobic faces (guest holes) downward and their hydrophilic groups upward. This generates an action and an effect of the hydrophilic group shedding the sebum and the sweat. Additionally, the persistently secreted sebum does not exhibit a stickily touch, but is a secretion that can be lightly and easily wiped off with, for example, a tissue. The fine powder of the invention of the present application complements the effects, ensuring maintaining the feel of smoothness on the skin surface for a long time.
- The application of the aluminum chloride fine powder and the cyclodextrin fine powder does not bring the action and the effect of inhibiting the sudden itch and the inflammation by themselves. However, the constitution of the emulsion barrier complex by the interaction of the degenerative stratum corneum, the aluminum chloride, the cyclodextrin, and the moisture expresses the mechanism of action to effectively block the cycle of the itch and the dermatitis. Accordingly, the mechanism of action can also lead to a prevention of various kinds of inflammatory skin diseases.
- The invention of present application has assumed as follows. The itch that cannot be solved by the antiperspirant effect from the aluminum chloride is caused by the emulsion concentrated on the skin stratum corneum. The invention has focused on the interaction compounded by a water-repellent film effect from the aluminum chloride compound, the inclusion and absorption effects from the cyclodextrin, and the moisture. Thus, the invention has solved the mechanism for itch. Using the publicly-known and publicly used aluminum chloride compound as an antiperspirant, numerous sweating tests have been conducted. For example, the water solution of the aluminum compound is applied over the whole body, and a heat accumulation test has been conducted. From the result of the heat accumulation test, the following features have been proved. The main effect is not the antiperspirant effect but the water repellent effect. Further, the porous thin film, which easily transmits the sebum and the moisture, is formed. The invention has an effect of forming not only the degenerative stratum corneum but also a water-repellent film to a different solute in the water solution. The water-repellent film establishes a mechanism as if an interfacial phenomenon where the moisture is peeled from the solute occurs and this blocks the moisture. The following is considered. This mechanism acts as an effect to block the production of the emulsion, which will be the causative agent of itch. Alternatively, the mechanism demulsifies the emulsion and isolates the moisture and the sebum. Thus, the mechanism promotes the inclusion and absorption effects of the sebum with the cyclodextrin. The cyclodextrin that has absorbed and included the sebum forms free water and a colloidal emulsion. However, the concentration of moisture on the degenerative stratum corneum promotes a condensation effect and the cyclodextrin is gelatinized. This brings a favorable condition to absorb and secure the aqueous (Some of them are possibly oily.) causative agent of itch to between particles and the periphery of the CD. According to this, it is concluded that the itch is prevented. Thus, the present invention has been completed. Regarding this itch prevention effect, the itch prevention effect cannot be obtained in examples of single use of the respective aluminum chloride and cyclodextrin, which are described in detail in itch prevention effect experiment, which will be described later.
- <Working Example 1> conducted heat accumulation experiment with the anti-itching powder. With the anti-itching powder applied over the whole body, two tested persons, male and female, climbed a mountain and run to test for how much the heat accumulation occurs. The result is as follows.
- 1) During climbing: The tested persons completed a low mountain at the altitude of 380 m for about two and half hours back and forth. The external temperature was 27° C., and the humidity was 75%.
- The tested person (male): The body temperature after the exercise was 34.5 to 35.0° C., and the temperature before the climbing was 35.1 to 35.8° C.
- The tested person (female): The body temperature after the exercise was 34 to 34.5° C., and the temperature before the climbing was 34.5 to 34.7° C.
- 2) During running for 10 km: The tested persons completed the running for about one hour. The external temperature was 30° C., and the humidity was 73%.
- The tested person (male): The body temperature after the exercise was 34 to 35.0° C., and the body temperature before the running was 35 to 36° C.
- The tested person (female): The body temperature after the exercise was 34 to 34.5° C., and the body temperature before the running was 35 to 36.2° C.
- Considering from the above-described results, since both the climbing and the running involve an advantage where the sweating is significantly smooth and by a distinguished water repellent effect, the sweat is likely to flow, an increase in the body temperature was not initiated. That is, it has been proved that even if the anti-itching powder of the present invention is applied over the whole body, a state where the skin is not physiologically changed at all from the usual skin can be maintained.
- <Experimental Example of Itch Prevention Effect>
- Details of Experiment
- Purpose of Experiment The fine powder of the aluminum chloride hexahydrate and the cyclodextrin (referred to as the CD) were each used alone for application to the skin over the whole body. From the result, whether the itch prevention effect was able to be bodily sensed or not was determined through somesthetic testing.
- Participated Examinees three (male: 2, female: 1)
- Testing Method Fine powder compositions of Experiment 1 to Experiment 3 were applied to the skin over the whole body. The climbing of a low mountain (altitude: 300 to 400 m) of 2 to 20 km and running of 2 to 15 km were executed 100 times appropriately for all seasons and for two years with the respective samples. Whether the itch was clearly removed or not and the appearance of the itch was able to be prevented or not were measured setting eight hours from the test start as terminal time. During the period, the somesthetic testing was conducted for determination. The total count of itches developed without application of various kinds of fine powder agents to the skin over the whole body (the head, the face, the body, and the entire feet) was set to 100. The degree of the itch was indicated by a “proportion of itch.”
- Experiment 1. The somesthetic testing was conducted to determine whether the single use of the aluminum chloride fine powder was able to prevent the itch or not based on the following prescription example. The result is shown in the following. First, since the moisture absorption and the deliquescency are large, pulverization of the aluminum chloride hexahydrate is difficult. Moreover, for direct application to the skin, the aluminum chloride hexahydrate has a high pH and therefore initializes a skin disorder. Accordingly, as the fine powder base, which will be the basic, fine powder formed by combining the aluminum chloride hydrate was used to determine the itch prevention effect by the somesthetic testing. The following fine powder base, which becomes the basic, was employed. Commercially available 160-mesh pass activated zinc oxide of 40 g, talc of 40 g, and 100-mesh pass corn starch of 20 g were used. Powdery aluminum chloride hydrate of 15 g was combined with these materials. The combined material was crushed and mixed for 25 minutes with ball mill. The material was shaken with a 48-mesh screen to produce mixed fine powder.
- <Result> The proportion of itch was 99%. The itch was hardly removed.
- Experiment 2. The somesthetic testing was conducted to determine whether the single use of the cyclodextrin was able to prevent the itch or not based on the following four prescription examples. The result is shown in the following.
- 1. α-CD The result of testing the application of the fine powder alone to the skin over the whole body
- <Result>The proportion of itch was 100%. The itch was not removed. Feel of stickiness of the sweat over the whole body was strong, and the itch was not removed.
- 2. β-CD The result of testing the application of the fine powder alone to the skin over the whole body
- <Result> The proportion of itch was 100%. Feel of stickiness of the sweat over the whole body was strong, and the itch prevention effect was not able to be bodily sensed.
- 3. γ-CD The result of testing the application of the fine powder alone to the skin over the whole body
- <Result> The proportion of itch was 100%. Feel of stickiness of the sweat over the whole body was strong, and the itch prevention effect was not able to be bodily sensed.
- 4. The result of conducting the somesthetic testing by application of a material formed by adding and mixing the fine powder β-CD of 10 g to a basic base of 100 g to the skin over the whole body
- <Result> The proportion of itch was 100%. Although the feel of stickiness was significantly reduced, the itch prevention effect was not able to be bodily sensed.
- Experiment 3. Based on <Working Example 1> of the invention of the present application, the aluminum chloride and β-CD as the main ingredients were combined with the fine powder base, which becomes the basic. The anti-itching powder thus formed was applied to the skin over the whole body to conduct the somesthetic testing. The result is as follows. The test results using the α-CD and the β-CD had no significant difference.
- <Result> As the average value of the three examinees, the proportion of itch was in a range of 30 to 0, and the persons felt that the itch was restricted in the 70 percent of the entire test result.
- In 30 percent of the results among them, the proportion of itch was 5% or less.
- <Consideration> To conduct the above-described test, it is considered that the state of the skin is not constant through the year and is affected by temperature/humidity conditions of the external air to some extent. However, even considering errors, the itch prevention effect has been verified from the experiment result of the anti-itching powder of the invention of the present application.
- The anti-itching powder of the present invention has an advantage that can be used also during treatment with an ointment or a similar medicine. In some cases, this reduces a usage frequency of curative medicine and duration of treatment. It is also possible to present an optimal, satisfactory periods of use or to propose a new usage method also for diseased patients who dislike steroids for external application. The following further describes problematic diseases with concrete examples in detail.
- The application of the anti-itching powder composited with the main ingredients of the aluminum chloride and the cyclodextrin over the whole body reduces the stickiness on the skin surface and reduces a shine. For example, before bathing or after bathing, the anti-itching powder is applied over the entire facial surface. Even after the elapse of several hours, the entire forehead is smooth and the rash skin touch disappears.
- The accumulation of the sebum in pores (drops of sebum, lumps of sebum, and grains of sebum) on a nose, which is easily recognized, outstandingly reduces. The continuous application to the precordium and the shoulders to the back allows feeling apparent reduction in acnes and disappearance of the acnes. The reasons are considered as follows. The anti-itching powder of the present invention inhibits: 1) the expression of sudden itching and 2) penetration of the emulsion, which is constituted of the sweat and the sebum, related to an appearance of acute-phase folliculitis into the living epidermal cell layer and cells on a wall of hair follicle (a wall of the pores).
- Besides, although there are countless various kinds of inflammatory skin diseases, the initial lesion is papular dermatitis, and the target is mainly the roots of hair. Apart from the seriousness of the dermatitis and whether the sudden itch is noticed or not, with the papular dermatitis, the sudden itch is preceded. After an elapse of certain time, the dermatitis develops into papules. To scratch these papules, the healthy skin around the papules, which is not directly related to the papules, is also scratched, resulting in expansion of the disease.
- Further, the strength of scratch, whether the skin is strongly scratched by tiptoes, the skin is scratched so as to rub the skin by the pulps, the skin is scratched with a towel, or the skin is scratched over clothes; how long is the skin scratched and how long is the period of scratch; and under these situations, how long period and how strong extent the dermatitis keep occurring. These situations design and initialize various and variety of inflammatory skin diseases.
- The following describes the embodiments of the present invention.
- <Working Example 1>
- The aluminum chloride hexahydrate of 7 g and β-CD of 10 g were introduced into a ceramic ball mill together with the powder basic base of 100 g and were crushed around 15 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained. The zinc white of 40 g, the talc of 40 g, and the corn starch of 20 g were combined to produce the powder basic base.
- <Working Example 2>
- The aluminum chloride hexahydrate of 5 g and β-CD of 5 g were introduced into the ceramic ball mill together with the powder basic base of 100 g and were crushed and mixed for 15 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained. The zinc white of 50 g, the talc of 20 g, and the corn starch of 30 g were combined to produce the powder basic base.
- <Working Example 3>
- Aluminum chloride anhydrate of 5 g and each 4 g of α-CD, β-CD, and γ-CD, 12 g in total, were introduced to a mixer together with the powder basic base of 100 g and were mixed for 5 minutes. Thus, the anti-itching powder was obtained. The talc of 60 g, the corn starch of 30 g, silicic anhydride of 5 g, and sodium oxide of 5 g were combined to produce the powder basic base.
- <Working Example 4>
- Anhydrous alum of 20 g and β-CD of 5 g were introduced into the mixer together with the powder basic base of 100 g to obtain 65-mesh pass anti-itching powder. The zinc white of 40 g, the talc of 30 g, and the corn starch of 30 g were combined to produce the powder basic base.
- <Working Example 5>
- The aluminum chlorohydrate of 10 g and α-CD of 10 g were introduced to the ceramic ball mill together with the powder basic base of 100 g and were crushed around 25 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained. The zinc white of 40 g, the talc of 40 g, and the corn starch of 20 g were combined to produce the powder basic base.
- <Working Example 6>
- The aluminum chloride hexahydrate of 7 g and β-CD of 10 g were introduced to the ceramic ball mill together with the powder basic base of 100 g and were crushed around 15 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained. The zinc white of 40 g, the talc of 40 g, and the corn starch of 20 g were combined to produce the powder basic base.
- <Working Example 7>
- The aluminum chloride hexahydrate of 7 g and γ-CD of 8 g were introduced to the ceramic ball mill together with the powder basic base of 100 g and were crushed around 15 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained. The zinc white of 40 g, the talc of 40 g, and the corn starch of 20 g were combined to produce the powder basic base.
- <Working Example 8>
- The anhydrous alum of 20 g and β-CD of 10 g were introduced to the ceramic ball mill together with the powder basic base of 100 g and were crushed around 15 minutes. Thus, as the 48-mesh pass crushed mixture, the anti-itching powder was obtained. The zinc white of 40 g, the talc of 40 g, and the corn starch of 20 g were combined to produce the powder basic base.
- The emulsion is the cell disorder composition, which becomes an ignition factor of acute inflammation or triggers the acute inflammation, or the emulsion causes a growth of bacteria and smell Inhibiting the production of the emulsion for a certain period of time (around 36 hours to two weeks) provides the following effects.
- Except for the emulsion, as the factors for the pores to cause the inflammation, which is a part of a transition process to the dermatitis of the pores, influences from the ultraviolet rays, the steroid, and reactive oxygen have been known. However, the generation of the reactive oxygen means that the cell disorder has already been initialized from any cause.
- 1. The anti-itching powder inhibits a sequence of cycles of inflammation where the inflammation that has once occurred in the pores persists and then is reinforced little by little. It is said that a chain of inflammation is a process of: increasing the inflammation in the pores and growing the red eminences on the pores, which is bacterial infection caused by touching and rubbing the pores. However, it is reasonable to think that the persistent penetration of the emulsion is largely related to the persistence and the aggravation of inflammation prior to secondary infection with bacteria. The process that the inflammation reaction persists and is reinforced is named as the ‘cycle of inflammation.’ The main factor bringing the cycle of inflammation is the emulsion.
- 2. The anti-itching powder has an effect of naturally regresses the red eminences, namely, the folliculitis, becoming larger on the pores. The anti-itching powder prevents the emulsion from keeping repeatedly stimulating the folliculitis. Thus, the anti-itching powder has an action and an effect that naturally flattens the red inflammatory eminences on the pores without developing the eminences into suppuration and an accumulation of pus.
- 3. The anti-itching powder has an effect of soothing the sudden, strong itch. The anti-itching powder has an effect of preliminary preventing the itch caused by penetration of the emulsion into the epidermis from accumulation to the stratum corneum. The anti-itching powder also has an effect of preliminary preventing the expression of sudden itch when the sweat oozes. This reduces an occasion where patients with atopy and children sweat and scratch their heads, ears, external genitalias, and limb joints. This allows bringing effects not only preliminary preventing the appearance of eczema and dermatitis but also decreasing the range.
- To validate the effects, it should be considered that there are various causes as the cause of the eczema and dermatitis except for the emulsion. The causes include, for example, the ultraviolet rays, medicines (a fomentation, an external medicine, and an oral medicine), chemical substances, insects, and plants.
- 4. The anti-itching powder has an effect of reducing keratosis pilaris (rashes on the cheek and the arm). Although the anti-itching powder does not cure this disease itself, an acute phase before the pores are cornified is the folliculitis (acute dermatitis of the pores). A trigger factor that initializes the inflammation of the folliculitis is an accumulation of the emulsions consisted of the sweat and the sebum on the stratum corneum epidermidis around the pores. The aluminum chloride adheres to the entire stratum corneum to prevent the accumulation of the moisture inside the stratum corneum. So to speak, this forms the sponge-like stratum corneum epidermidis into like a single plate.
- The cornification of the keratosis pilaris means that the epidermal cells at the exit of the pores go through a denaturation and change into the inflammation, lose the nuclei, and are stacked, so-called accumulation of epidermis refuses. This forms the stratum corneum epidermidis at the exit of the pores into like the single plate to inhibit the accumulation of the emulsions. This allows preventing the inflammation and the denaturation of the cells. As a result, this prevents the cornification of the pores, and consequently ensuring preventing the keratosis pilaris. The effect can be felt in a short period (one to two weeks). This is because that the inflammation of the skin leading to the keratosis pilaris is much lighter than the inflammation of the acne.
- 5. The anti-itching powder has an action and effect of outstandingly preventing oxidized colors of the unsaturated fatty acid secreted from the sebaceous gland, mainly yellow stains on clothing generated by the secretion of the apocrine gland.
- 6. The stickiness of the sweat generated by excessive sweating on the hand is not only the moisture but also is the emulsion consisted of the sweat and the sebum. The surface-active effect by the aluminum chloride and the CD blocks and inhibits the emulsion accumulated on the stratum corneum epidermidis. This provides a smooth texture to a person who has touched the hand.
- 7. The anti-itching powder with the main ingredients of the aluminum chloride and the cyclodextrin is in a category of quasi-drug. Therefore, like an insect repellent, the anti-itching powder can be casually used, anytime and anywhere regardless of frequency. Accordingly, the anti-itching powder is also excellent in convenience.
- The skin-degenerative stratum corneum, the aluminum chloride, water, and the cyclodextrin construct the emulsion barrier complex. This expresses the mechanism of action to effectively block the cycle of dermatitis. This allows bringing prevention of various inflammatory skin diseases. The anti-itching powder of the present invention has an advantage that can be used also during treatment with the ointment or a similar medicine. In some cases, this substantially reduces a usage frequency of curative medicine and duration of treatment. It is also possible to present an optimal, satisfactory periods of use or to propose a new usage method also for diseased patients who dislike steroids for external application. The anti-itching powder features extremely high effectiveness as one means for alternative medicine. The anti-itching powder is an invention that provides great anticipation and prospect for treatment strategy of these diseases.
- Note that, this invention is not limited to the above-mentioned embodiments. Although it is to those skilled in the art, the following are disclosed as the one embodiment of this invention.
- Mutually substitutable members, configurations, etc. disclosed in the embodiment can be used with their combination altered appropriately.
- Although not disclosed in the embodiment, members, configurations, etc. that belong to the known technology and can be substituted with the members, the configurations, etc. disclosed in the embodiment can be appropriately substituted or are used by altering their combination.
- Although not disclosed in the embodiment, members, configurations, etc. that those skilled in the art can consider as substitutions of the members, the configurations, etc. disclosed in the embodiment are substituted with the above mentioned appropriately or are used by altering its combination.
- While the invention has been particularly shown and described with respect to preferred embodiments thereof, it should be understood by those skilled in the art that the foregoing and other changes in form and detail may be made therein without departing from the sprit and scope of the invention as defined in the appended claims.
Claims (2)
1. Anti-itching powder as a compound fine powder, comprising:
a fine powder containing main ingredients of aluminum chloride and cyclodextrin; and
a basis fine powder as a base, the basis fine powder being combined with the fine powder, wherein
the compound fine powder is for application over a skin surface to confine an emulsion to skin-degenerative stratum corneum, the emulsion being consisted of persistent sweat and sebum, the compound fine powder being configured to block a penetration of the emulsion up to an epidermal cell, and
the anti-itching powder does not contain porous powder made by compounding silicon dioxide and magnesium oxide as main raw materials.
2. Anti-itching powder as a compound fine powder, comprising:
a fine powder containing main ingredients of alum and cyclodextrin; and
a basis fine powder as a base, the basis fine powder being combined with the fine powder, wherein
the compound fine powder is for application over a skin surface to confine an emulsion to skin-degenerative stratum corneum, the emulsion being consisted of persistent sweat and sebum, the compound fine powder being configured to block a penetration of the emulsion up to an epidermal cell, and
the anti-itching powder does not contain porous powder made by compounding silicon dioxide and magnesium oxide as main raw materials.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/138,229 US10272104B2 (en) | 2014-07-20 | 2016-04-26 | Method for treating itch |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-160819 | 2014-07-20 | ||
JP2014160819A JP5824704B1 (en) | 2014-07-20 | 2014-07-20 | Powder-like stagnation agent |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/138,229 Division US10272104B2 (en) | 2014-07-20 | 2016-04-26 | Method for treating itch |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160015637A1 true US20160015637A1 (en) | 2016-01-21 |
Family
ID=54696335
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/799,591 Abandoned US20160015637A1 (en) | 2014-07-20 | 2015-07-15 | Anti-itching powder |
US15/138,229 Active 2036-01-16 US10272104B2 (en) | 2014-07-20 | 2016-04-26 | Method for treating itch |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/138,229 Active 2036-01-16 US10272104B2 (en) | 2014-07-20 | 2016-04-26 | Method for treating itch |
Country Status (2)
Country | Link |
---|---|
US (2) | US20160015637A1 (en) |
JP (1) | JP5824704B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5998399B1 (en) * | 2015-09-10 | 2016-09-28 | 株式会社ライラック研究所 | Itching prevention agent |
JP6232631B2 (en) * | 2016-04-18 | 2017-11-22 | 株式会社ライラック研究所 | Biofilm agent |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635165A (en) * | 1995-09-27 | 1997-06-03 | Helene Curtis, Inc. | Antiperspirant deodorant compositions |
US5780020A (en) | 1996-10-28 | 1998-07-14 | The Proctor & Gamble Company | Methods and compositions for reducing body odor |
US5861143A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Methods for reducing body odors and excess moisture |
AR029184A1 (en) * | 2000-01-06 | 2003-06-18 | Marantech Holding Llc | PHARMACEUTICAL COMPOSITIONS USEFUL TO PREVENT AND / OR TREAT DERMATOLOGICAL DISEASES AND TO FACILITATE AND / OR INCREASE THE GROWTH OF THE SKIN AND THE FABRICS THAT INCLUDE SUCH COMPOSITIONS |
JP2003073249A (en) * | 2001-08-30 | 2003-03-12 | Lion Corp | Deodorant composition |
WO2004035071A1 (en) | 2002-10-17 | 2004-04-29 | Nakar, Herzl | Herbal medicine containing cyclodextrins for the treatment of ear disorders |
JP4274354B2 (en) * | 2003-04-04 | 2009-06-03 | 株式会社資生堂 | Topical skin preparation |
US7351747B2 (en) * | 2003-01-06 | 2008-04-01 | Gilbert Buchalter | Skin treatment for relief of itch |
JP5254527B2 (en) * | 2005-08-31 | 2013-08-07 | ライオン株式会社 | Male odor control agent |
-
2014
- 2014-07-20 JP JP2014160819A patent/JP5824704B1/en not_active Expired - Fee Related
-
2015
- 2015-07-15 US US14/799,591 patent/US20160015637A1/en not_active Abandoned
-
2016
- 2016-04-26 US US15/138,229 patent/US10272104B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP5824704B1 (en) | 2015-11-25 |
JP2016023183A (en) | 2016-02-08 |
US10272104B2 (en) | 2019-04-30 |
US20160235784A1 (en) | 2016-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3013477A1 (en) | Moisturizing compositions and uses thereof | |
CN102342993B (en) | Anti-sensitization and restoration external preparation for skin | |
CN105107007B (en) | A kind of medical protective dressing of cation and preparation method thereof | |
WO2017100873A1 (en) | Cosmetic composition and use thereof | |
JP2002053428A (en) | Skin care preparation | |
JP2006525945A (en) | External composition to be administered through the skin | |
KR20090054777A (en) | Composition for regulating pΗ of skin and cosmetics comprising same | |
ES2431320T3 (en) | Use of the association of the tyrosine-arginine dipeptide and niacinamide as a substance P antagonist | |
US10272104B2 (en) | Method for treating itch | |
AU2020418843A1 (en) | PPAR agonist complex and methods of use | |
US20170035802A1 (en) | Method for treating itching | |
JP5895244B2 (en) | Functional lotion | |
KR20120078810A (en) | Cosmetics composition for skin conditions comprising methyl sulfonyl methane, alum | |
JP5704809B2 (en) | External preparation for skin and pruritus | |
US20170035801A1 (en) | Anti-itching agent | |
WO2016033899A1 (en) | Dandruff removing composition for adjusting scalp oil balance | |
JP5429851B2 (en) | Active oxygen scavenger, skin external preparation and cosmetic using the active oxygen scavenger | |
JPH10298057A (en) | Bath composition | |
CN105169463B (en) | A kind of cation baby's medical dressing and preparation method thereof | |
JPS61246130A (en) | External agent for stimulation skin cell activity | |
KR102089290B1 (en) | Cosmetic composition for improving skin wrinkles and elasticity | |
JP6656553B1 (en) | Beauty method | |
JP2004075635A (en) | Moisturizing agent and external preparation for skin | |
JP6665848B2 (en) | Skin cosmetic food composition and cosmetic composition containing sugar solution containing galacto-oligosaccharide at high ratio | |
HK1253779A1 (en) | Anti-itching agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LILAC LABORATORY CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HIRAIWA, RYOICHI;REEL/FRAME:036674/0369 Effective date: 20150903 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |